{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"AZD 9833"},{"type":"CodeName","name":"AZD9833"},{"type":"LexicalVariant","name":"selective estrogen receptor degrader AZD9833"},{"type":"Synonym","name":"SERD AZD9833"},{"type":"CASRegistryName","name":"2222844-89-3"},{"type":"CodeName","name":"AZ-14066724"},{"type":"CodeName","name":"AZD-9833"},{"type":"Synonym","name":"N-(1-(3-fluoropropyl)-3-azetidinyl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo(4,3-f)isoquinolin-6-yl)-3-pyridinamine"}],"definition":{"html":"An orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon administration, camizestrant binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells.","text":"An orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon administration, camizestrant binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells."},"drugInfoSummaryLink":null,"nciConceptId":"C160603","nciConceptName":"Camizestrant","termId":799429,"name":"camizestrant","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"camizestrant"}],"links":null}